Rapid isolation of single-chain antibodies by phage display technology directed against one of the most potent marine toxins: Palytoxin

Gambierdiscus and Ostreopsis: Reassessment of the state of knowledge of their taxonomy, geography, ecophysiology, and toxicology

“…A competitive immunoassay was developed for MTX (Bignami et al, 1996). Several antibodybased assays have been used for the detection of the PTX-class of toxins including radioimmunoassays (Levine et al, 1988), ELISA (Bignami et al, 1992;Garet et al, 2010), hemolysis neutralization assays (Bignami, 1993), and the recently described surface plasmon resonance biosensor (Yakes et al, 2011); the most robust of these methods to date (i.e., providing rapid and sensitive PTX concentration determination in seafood matrices).…”

Construction of single-chain variable fragment antibodies against MCF-7 breast cancer cells

“…scFv have demonstrated to be a particularly useful tool for clinical and medical applications, since they are only half the size of fragment antibodies (Fabs) and thus have lower retention times in non-target tissue, more rapid blood clearance and better tumor penetration (Huston et al, 1996;Marasco et al, 1998). Phage displayed technology is a system that makes it possible to generate scFvs with desired binding affinity and specificities (Garet et al, 2010;Pande et al, 2010). In the present study, we demonstrated the construction of anti-MCF-7 scFv antibodies specific to human breast cancer cells by phage display technology.…”

Selection and characterization of single-chain recombinant antibodies against spring viraemia of carp virus from mouse phage display library

“…The application of phage display technology for the generation of monoclonal antibodies against even the most difficult targets, such as small molecules, represents a promising alternative to traditional hybridoma technology (Garet et al, 2010). This technique for the production of recombinant antibodies has several advantages: rapid culture of phage clones; easy handling and detection of secreted antibodies; genetic stability; lower production costs compared with MAbs (Johns et al, 2000;Foy et al, 2002).…”